MiNK Therapeutics iNKT platform joins ARPA-H-funded room-temperature cell therapy program
INKT•MiNK Therapeutics’ agenT-797 iNKT platform was selected for an ARPA-H-funded effort to enable room-temperature storage of cell therapies. The four-year program has up to $87 million committed across the initiative.
1. Program participation
MiNK Therapeutics’ agenT-797 iNKT platform was selected for ARPA-H’s BioStabilization Systems program, which aims to enable room-temperature storage of cell therapies. MiNK joins the Reversible Ambient Biostabilization team led by Draper, with Likarda and Fresenius Kabi among the participants; up to $87 million is committed across the four-year initiative.
